Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Blacks Fare Better After This Type of Transplant

Biol Blood Marrow Transplant.; ePub 2018 Jan 25; Solomon, et al

Black patients appear to experience less disease relapse than whites following post-transplant cyclophosphamide-based haploidentical donor transplantation (PTCy-HIDT), according to an analysis involving 203 individuals. Participants were a median age of 53 years and comprised blacks (n=80) and whites (n=123) who underwent first PTCy-HIDT for hematologic malignancies at a single center. Peripheral blood stem cell was used in two-thirds of patients, and 4 in every 10 received myeloablative conditioning. Among the results:

  • 3-year overall survival, disease-free survival, and relapse rates in blacks were 72%, 65%, and 25%, respectively.
  • These rates in whites were 50%, 45%, and 39%, respectively.
  • Non-relapse mortality, acute graft-versus-host disease (GVHD), and moderate-to-severe chronic GVHD rates were similar in both groups.
  • Improved survival was seen in all black patient subgroups.
  • Blacks were 53% more likely than whites to experience better overall survival.
  • They were 51% more likely to experience better disease-free survival.


Solomon S, Zhang X, Holland H, Morris L, Solh M, Bashey A. Superior survival of black versus white patients following post-transplant cyclophosphamide-based haploidentical transplantation for adults with hematologic malignancy. [Published online ahead of print January 25, 2018]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2018.01.024.

This Week's Must Reads

Widespread Zika screens not cost effective, Saá P et al. New Engl J Med. 2018;378:1778-88. doi: 10.1056/NEJMoa1714977

New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

Good ALL outcomes in Down syndrome children, Maloney K et al. ASPHO 2018, annual meeting of the American Society of Pediatric Hematology/Oncology Abstract PP 2001

Reducing morbidity in postpartum hemorrhage, Smith R et al. Annual clinical and scientific meeting of the American Society of Obstetricians and Gynecologists 2018, Abstract 26R.

In sickle cell, start hydroxyurea in infancy, Schuchard S et al. ASPHO 2018, poster # 342 Schuchard S et al. ASPHO 2018, poster # 342.

Must Reads in Myelodysplastic Syndrome

Romiplostim safety confirmed in thrombocytopenic patients with low-risk myelodysplastic syndromes, Kantarjian H et al. The Lancet Haematology March 2018, Pages e117-e126

Simplifying the URD Selection Process for HCT, Biol Blood Marrow Transplant.; ePub 2018 Feb 14; Shaw, Logan, et al

Genetic Risk Model for MDS Shown to Be Feasible, Am J Hematol; ePub 2018 Feb 24; Gangat, et al

This Predicts Risk of Early Relapse, Death in MM , Biol Blood Marrow Transplant; ePub 2018 Feb 23; Cowan, et al

Undertreatment of Newly-Diagnosed MM Evaluated, Clin Lymphoma Myeloma Leuk; ePub 2018 Feb 3; Fakhri, et al